BioSpace News Archive

Drug Development

FDA Greenlights Lilly Early Breast Cancer Drug - with a Caveat

The drug is limited to patients who test at least 20% for a Ki-67 score on an FDA-approved test.

October 13, 2021
·
2 min read
·
Mark Terry
Drug Development

Glimmers of Hope in MS as Genentech, Sanofi and Biogen Present at ECTRIMS

At the virtual Congress of the ECTRIMS meeting this week, multiple companies present data for ongoing studies of therapies for multiple sclerosis. BioSpace takes a look at some of the data.

October 13, 2021
·
4 min read
·
Alex Keown
BioMidwest

Busting the COVID-19 Vaccine and Infertility Myth

It’s not the COVID-19 vaccine that will get you. The real cause for concern is the virus, and it lies in the fact that both male and female reproductive organs contain cell receptors the virus targets.

October 13, 2021
·
2 min read
·
Heather McKenzie
Drug Development

CRISPR Therapeutics’ CAR-T Cancer Therapy Shows Early Promise

CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.

October 13, 2021
·
3 min read
·
Mark Terry
Deals

Life Sciences IPO Scene Buzzing So Far in October

It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.

October 13, 2021
·
2 min read
·
Ellen Camacho
Drug Development

Venatorx’s Path to Novel Antibiotics – and Stopping another Pandemic

Less private investment and innovation in the development of new antibiotics are impeding efforts to combat drug-resistant infections.

October 13, 2021
·
7 min read
·
Joseph Constance
Business

Takeda Doubles Down on Biotech Partnerships with Immusoft and Poseida

Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.

October 13, 2021
·
3 min read
·
Mark Terry
BioMidwest

Money on the Move: October 6 – 12

Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week.

October 13, 2021
·
4 min read
·
Kate Goodwin
FDA

FDA Experts: Case is Inconclusive for Moderna Vaccine Booster

The FDA said that there had been concerns over the reduced effectiveness of the Moderna COVID-19 vaccine against symptomatic disease.

October 13, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

Intellia and SparingVision See Eye to Eye in New Partnership

Genome-editing company Intellia Therapeutics and France-based SparingVision have partnered to develop new therapies for ocular diseases. The deal could be worth up to $600 million for Intellia.

October 13, 2021
·
3 min read
·
Alex Keown